| Host |
Rabbit |
| Clone |
Polyclonal |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Brain |
| Dilution |
1:50 - 1:100 |
| Localization |
Cytoplasm, extracellular |
Amyloid
|
Diagnostic Biosystems |
Polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP123-05 |
-
|
| Host |
Mouse |
| Clone |
mc1 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Kidney |
| Dilution |
1:10 - 1:25 |
| Isotype |
Mouse IgG2a |
| Localization |
Extracellular |
Amyloid A Component
|
Diagnostic Biosystems |
mc1 |
1 ml |
Concentrate |
CE/IVD |
MOB003 |
-
|
| Host |
Mouse |
| Clone |
mc1 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Kidney |
| Dilution |
1:10 - 1:25 |
| Isotype |
Mouse IgG2a |
| Localization |
Extracellular |
Amyloid A Component
|
Diagnostic Biosystems |
mc1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB003-01 |
-
|
| Host |
Mouse |
| Clone |
mc1 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Kidney |
| Dilution |
1:10 - 1:25 |
| Isotype |
Mouse IgG2a |
| Localization |
Extracellular |
Amyloid A Component
|
Diagnostic Biosystems |
mc1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB003-05 |
-
|
| Host |
Mouse |
| Clone |
DE2B4 |
| Format |
Purified |
| Method |
WB, P, IP |
| Pretreatment |
Enzyme |
| Positive control |
Alzheimer´s disease brain |
| Isotype |
Mouse IgG1 |
| Immunogen |
Synthetic peptide consisting of residues 1-17 of the amyloid beta protein |
Amyloid Beta
|
Zytomed Systems GmbH |
DE2B4 |
100 µg |
Purified |
RUO |
601-0210 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Serum |
| Method |
EL, WB, P |
| Pretreatment |
Formic acid |
| Positive control |
Alzheimer´s disease brain |
| Isotype |
Rabbit IgG |
Amyloid Beta 1 - 40
|
Zytomed Systems GmbH |
polyclonal |
100 µl |
Serum |
RUO |
601-0211 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Serum |
| Method |
EL, WB, P |
| Pretreatment |
Formic acid |
| Positive control |
Alzheimer´s disease brain |
| Isotype |
Rabbit IgG |
Amyloid Beta 1 - 42
|
Zytomed Systems GmbH |
polyclonal |
100 µl |
Serum |
RUO |
601-0212 |
-
|
| Host |
Mouse |
| Clone |
BAM-10 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Brain |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Amyloid Beta Protein
|
Diagnostic Biosystems |
BAM-10 |
1 ml |
Concentrate |
CE/IVD |
MOB410 |
-
|
| Host |
Mouse |
| Clone |
BAM-10 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Brain |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Amyloid Beta Protein
|
Diagnostic Biosystems |
BAM-10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB410-01 |
-
|
| Host |
Mouse |
| Clone |
BAM-10 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Brain |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Amyloid Beta Protein
|
Diagnostic Biosystems |
BAM-10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB410-05 |
-
|
| Host |
Mouse |
| Clone |
AR 441 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Prostate Carcinoma |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Androgen Receptor
|
Diagnostic Biosystems |
AR 441 |
1 ml |
Concentrate |
CE/IVD |
MOB245 |
-
|
| Host |
Mouse |
| Clone |
AR 441 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Prostate Carcinoma |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Androgen Receptor
|
Diagnostic Biosystems |
AR 441 |
0.1 ml |
Concentrate |
CE/IVD |
MOB245-01 |
-
|
| Host |
Mouse |
| Clone |
AR 441 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Prostate Carcinoma |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Androgen Receptor
|
Diagnostic Biosystems |
AR 441 |
0.5 ml |
Concentrate |
CE/IVD |
MOB245-05 |
-
|
| Host |
Mouse |
| Clone |
AR 441 |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Prostate Carcinoma |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Androgen Receptor
|
Diagnostic Biosystems |
AR 441 |
6 ml |
Ready-to-use |
CE/IVD |
PDM167 |
-
|
| Host |
Rabbit |
| Clone |
ZR334 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Prostate or Breast Carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide corresponding ti residues (within aa 1-100) of human Androgen Receptor |
| Localization |
Nucleus |
Androgen Receptor (AR)
|
Zeta Corporation |
ZR334 |
1 ml |
Concentrate |
CE/IVD |
Z2640RL |
-
|
| Host |
Rabbit |
| Clone |
ZR334 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Prostate or Breast Carcinoma |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide corresponding ti residues (within aa 1-100) of human Androgen Receptor |
| Localization |
Nucleus |
Androgen Receptor (AR)
|
Zeta Corporation |
ZR334 |
7 ml |
Ready-to-use |
CE/IVD |
Z2640RP |
-
|
| Host |
Rabbit |
| Clone |
ZR334 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Prostate or Breast Carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide corresponding ti residues (within aa 1-100) of human Androgen Receptor |
| Localization |
Nucleus |
Androgen Receptor (AR)
|
Zeta Corporation |
ZR334 |
0.5 ml |
Concentrate |
CE/IVD |
Z2640RS |
-
|
| Host |
Rabbit |
| Clone |
ZR334 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Prostate or Breast Carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide corresponding ti residues (within aa 1-100) of human Androgen Receptor |
| Localization |
Nucleus |
Androgen Receptor (AR)
|
Zeta Corporation |
ZR334 |
0.1 ml |
Concentrate |
CE/IVD |
Z2640RT |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Purified |
| Method |
WB, P |
| Pretreatment |
Citrate |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to a sequence within the amino acid terminus of human ACE2 |
Angiotensin Converting Enzyme 2 (ACE2)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Purified |
RUO |
601-0006 |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM211 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Lymph node or hairy cell leukemia |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2a /κ |
| Immunogen |
Recombinant full-length human Annexin A1 protein |
| Localization |
Nucleus, cytoplasm or cell membrane |
Annexin A1
|
Zeta Corporation |
ZM211 |
1 ml |
Concentrate |
CE/IVD |
Z2488ML |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM211 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Lymph node or hairy cell leukemia |
| Dilution |
- |
| Isotype |
IgG2a /κ |
| Immunogen |
Recombinant full-length human Annexin A1 protein |
| Localization |
Nucleus, cytoplasm or cell membrane |
Annexin A1
|
Zeta Corporation |
ZM211 |
7 ml |
Ready-to-use |
CE/IVD |
Z2488MP |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM211 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Lymph node or hairy cell leukemia |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2a /κ |
| Immunogen |
Recombinant full-length human Annexin A1 protein |
| Localization |
Nucleus, cytoplasm or cell membrane |
Annexin A1
|
Zeta Corporation |
ZM211 |
0.5 ml |
Concentrate |
CE/IVD |
Z2488MS |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM211 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Lymph node or hairy cell leukemia |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2a /κ |
| Immunogen |
Recombinant full-length human Annexin A1 protein |
| Localization |
Nucleus, cytoplasm or cell membrane |
Annexin A1
|
Zeta Corporation |
ZM211 |
0.1 ml |
Concentrate |
CE/IVD |
Z2488MT |
-
|
| Host |
Mouse |
| Clone |
1/A5F6 |
| Format |
Purified |
| Method |
F, P, EL, WB, IP |
| Pretreatment |
Citrate |
| Positive control |
Kidney |
| Dilution |
1:500 - 1:1000 (P) |
| Isotype |
Mouse IgG1 |
| Immunogen |
Synthetic peptide corresponding to amino acids 249-269 of rat aquaporin 1 |
Aquaporin 1
|
Zytomed Systems GmbH |
1/A5F6 |
100 µg (100 µl) |
Purified |
RUO |
601-0278 |
-
|
| Host |
Rabbit |
| Clone |
SP156 |
| Format |
Concentrate |
| Reactivity |
BV,PG,RB |
| Method |
P |
| Pretreatment |
EDTA |
| Dilution |
1:100 |
| Immunogen |
Synthetic peptide derived from the C-terminus of human arginase-1 protein |
Arginase-1
|
Zytomed Systems GmbH |
SP156 |
0.1 ml |
Concentrate |
RUO |
501-4560 |
-
|
| Host |
Rabbit |
| Clone |
SP156 |
| Format |
Concentrate |
| Reactivity |
BV,PG,RB |
| Method |
P |
| Pretreatment |
EDTA |
| Dilution |
1:100 |
| Immunogen |
Synthetic peptide derived from the C-terminus of human arginase-1 protein |
Arginase-1
|
Zytomed Systems GmbH |
SP156 |
0.5 ml |
Concentrate |
RUO |
501-4562 |
-
|
| Host |
Rabbit |
| Clone |
SP156 |
| Format |
Concentrate |
| Reactivity |
BV, PG, RB |
| Method |
P |
| Pretreatment |
EDTA |
| Dilution |
1:100 |
| Immunogen |
Synthetic peptide derived from the C-terminus of human arginase-1 protein |
Arginase-1
|
Zytomed Systems GmbH |
SP156 |
1 ml |
Concentrate |
RUO |
501-4564 |
-
|
| Host |
Rabbit |
| Clone |
EP261 (previously known as EPR6672(B)) |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Normal human liver |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasma and nucleus |
Arginase-1
|
Biocare Medical |
EP261 (previously known as EPR6672(B)) |
0.1 ml |
Concentrate |
CE/IVD |
ACI3058A |
-
|
| Host |
Rabbit |
| Clone |
EP261 (previously known as EPR6672(B)) |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Normal human liver |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasma and nucleus |
Arginase-1
|
Biocare Medical |
EP261 (previously known as EPR6672(B)) |
0.5 ml |
Concentrate |
CE/IVD |
ACI3058B |
-
|
| Host |
Rabbit |
| Clone |
EP261 (previously known as EPR6672(B)) |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Normal human liver |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasmic and nuclear |
Arginase-1
|
Biocare Medical |
EP261 (previously known as EPR6672(B)) |
6 ml |
Ready-to-use |
CE/IVD |
API3058AA |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Purified |
| Method |
WB, P |
| Pretreatment |
keine |
| Positive control |
Herz |
| Dilution |
5 µg/mL |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to a portion of the amino acid sequence between 300-450 of human ATG4-KLH conjugated |
ATG4B
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Purified |
RUO |
601-0367 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Normal prostate |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Localization |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
0.1 ml |
concentrate |
CE/IVD |
ACI3251A |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Normal prostate |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Localization |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
1 ml |
concentrate |
CE/IVD |
ACI3251C |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Normal prostate |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
7 ml |
Ready-to-use |
CE/IVD |
ALI3251G7 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Normal prostate |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API3251AA |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Normal prostate |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
AVI3251G |
-
|
| Host |
Mouse |
| Clone |
D-5 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
EDTA Puffer, pH 8,0 |
| Positive control |
Pancreas |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG2a kappa |
| Immunogen |
raised against amino acids 2193- 2492 mapping near the Cterminus of ATRX of human origin |
| Localization |
nuclear |
ATRX
|
Diagnostic Biosystems |
D-5 |
1 ml |
Concentrate |
CE/IVD |
MOB600 |
-
|
| Host |
Mouse |
| Clone |
D-5 |
| Format |
ready-to-use |
| Method |
F, P |
| Pretreatment |
EDTA Puffer, pH 8,0 |
| Positive control |
Pancreas |
| Dilution |
--- |
| Isotype |
Mouse IgG2a kappa |
| Immunogen |
raised against amino acids 2193- 2492 mapping near the Cterminus of ATRX of human origin |
| Localization |
nuclear |
ATRX
|
Diagnostic Biosystems |
D-5 |
6 ml |
ready-to-use |
CE/IVD |
PDM600 |
-
|
| Host |
Mouse |
| Clone |
35C1 |
| Format |
Purified |
| Method |
WB, IP, IF |
| Isotype |
Mouse IgG2b |
| Immunogen |
Recombinant Aurora-A |
Aurora A Kinase
|
Zytomed Systems GmbH |
35C1 |
100 µg |
Purified |
RUO |
601-0320 |
-
|
| Host |
Mouse |
| Clone |
2213 |
| Format |
Purified |
| Method |
EL |
| Isotype |
Mouse IgG1 |
| Immunogen |
Highly pure beta-2-microglobulin from human urine |
b2-Microglobulin
|
Zytomed Systems GmbH |
2213 |
1 mg |
Purified |
RUO |
602-0004 |
-
|
| Host |
Mouse |
| Clone |
B2M-01 |
| Format |
Purified |
| Method |
EL, FL |
| Isotype |
Mouse IgG2a |
| Immunogen |
Beta-2-microglobulin from human urine |
b2-Microglobulin
|
Zytomed Systems GmbH |
B2M-01 |
250 µg |
Purified |
RUO |
602-0005 |
-
|
| Host |
Mouse |
| Clone |
TLD-3H12B |
| Format |
Purified |
| Method |
F, WB, FL |
| Isotype |
Mouse IgG1 |
| Immunogen |
Rat microglial cells |
b2-Microglobulin
|
Zytomed Systems GmbH |
TLD-3H12B |
250 µg |
Purified |
RUO |
602-0007 |
-
|
| Host |
Mouse |
| Clone |
TLD-3H12B |
| Format |
Purified |
| Method |
F, WB, FL |
| Isotype |
Mouse IgG1 |
| Immunogen |
Rat microglial cells |
b2-Microglobulin
|
Zytomed Systems GmbH |
TLD-3H12B |
100 µg |
Purified |
RUO |
602-0008 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Mesothelioma, Melanoma, Normal testis |
| Dilution |
1:50 |
| Isotype |
Rabbit IgG |
| Localization |
Nuclear |
BAP1
|
Biocare Medical |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
ACI3247A |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Mesothelioma, Melanoma, Normal testis |
| Dilution |
1:50 |
| Isotype |
Rabbit IgG |
| Localization |
Nuclear |
BAP1
|
Biocare Medical |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
ACI3247B |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Mesothelioma, Melanoma, Normal testis |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Nuclear |
BAP1
|
Biocare Medical |
polyclonal |
7 ml |
Ready-to-use |
CE/IVD |
ALI3247G7 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Mesothelioma, Melanoma, Normal testis |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Nuclear |
BAP1
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API3247AA |
-
|
| Host |
Rabbit |
| Clone |
ZR454 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Malignant Mesothelioma |
| Dilution |
RTU |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide against 430-729 of human BAP1 |
| Localization |
Nuclear |
BAP1
|
Zeta Corporation |
ZR454 |
7.0 ml |
Ready-to-use |
RUO |
Z2813RP-R |
-
|
| Host |
Rabbit |
| Clone |
ZR454 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Malignant Mesothelioma |
| Dilution |
1:100-20 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide against 430-729 of human BAP1 |
| Localization |
Nuclear |
BAP1
|
Zeta Corporation |
ZR454 |
0.5 ml |
Concentrate |
RUO |
Z2813RS-R |
-
|
| Host |
Mouse |
| Clone |
C-4 |
| Format |
ready-to-use |
| Method |
FFPE |
| Pretreatment |
EDTA |
| Positive control |
Breast Carcinoma |
| Dilution |
--- |
| Isotype |
IgG1, kappa |
| Immunogen |
Synthetic peptide against 430-729 of human BAP1 |
| Localization |
nuclear and cytoplasmic |
BAP1 (BRCA1-Associated Protein 1)
|
Diagnostic Biosystems |
C-4 |
6 ml |
ready-to-use |
CE/IVD |
PDM595 |
-
|